Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Syntiron US$1.7 million to develop a maternal vaccine that targets Escherichia coli and Klebsiella pneumoniae, two bacterial species that cause a large portion of neonatal sepsis infections.
Tr1x Inc. announced a $75 million series A financing to advance universal allogeneic regulatory T (Treg) and chimeric antigen receptor (CAR)-Treg cell therapies into the clinic to treat autoimmune and inflammatory diseases.
Kyverna Therapeutics Inc. disclosed a filing to raise up to $100 million in an IPO, becoming the sixth firm to announce plans for a U.S. listing in the new year, offering tentative hope that the public markets might prove more welcoming to biopharma firms after a lackluster 2023.
Current risk genes for some diseases such as multiple sclerosis (MS) may have emerged in the past as protection against infection by different pathogens. A group of researchers led by scientists from the University of Copenhagen has analyzed the ancient DNA of European populations and has revealed how MS, Alzheimer’s disease (AD) and diabetes arose as populations migrated. This evolution would explain the modern genetic diversity and the incidences of these pathologies observed today in the old continent.
Intravacc BV has been awarded funding for up to $633,000 from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) for the development of a preventive vaccine against Neisseria gonorrhoeae (NG), the bacterium that causes gonorrhea.
Exevir Bio BV has released new data demonstrating that its antibodies are highly potent in neutralizing currently circulating COVID-19 omicron variants.
CC-chemokine receptor 3 (CCR3) is a member of the G protein-coupled, seven-transmembrane receptor family expressed on mouse eosinophils, basophils, mast cells and mononuclear phagocytes, among others, that plays a role in allergic diseases such as allergic rhinitis.
CD38 is the main NAD+-hydrolyzing enzyme, and it also catabolizes nicotinamide mononucleotide (NMN) and other extracellular NAD+ precursors prior to their intracellular transport for NAD+ biosynthesis.
Current risk genes for some diseases such as multiple sclerosis (MS) may have emerged in the past as protection against infection by different pathogens. A group of researchers led by scientists from the University of Copenhagen has analyzed the ancient DNA of European populations and has revealed how MS, Alzheimer’s disease (AD) and diabetes arose as populations migrated. This evolution would explain the modern genetic diversity and the incidences of these pathologies observed today in the old continent.
RSS
